sharp peak of ALL incidence is observed at 2-5 years of age. 2 There has been a gradual increase in the incidence of ALL in the past 2 5 y ears. 3 Hopefully survival rates for ALL have improved dramatically since 1980s with a current five-year overall survival r a tes greater than 85%. [4] [5] [6] This improvement is due to treatment of a large number of children in sequential standardised r esearch protocols. Treatment of children with ALL is divided into several stages: remission induction, consolidation or intensification, and maintenance (continuation) therapy with CNS prophylaxis therapy generally provided in each stage.
The goal of induction therapy is to bring the disease into remission (patient's blood counts return to normal and bone marrow shows no signs of disease). Usually three-drug induction therapy using vincristine, prednisolone/dexamethasone, plus Lasparaginase in conjunction with intrathecal therapy (IT) results in complete remission rates of greater than 95%. [7] [8] [9] Patients with increased risk require anthracycline (e.g., daunomycin). Protocols using this 4-drug combination with intensive consolidation and maintenance therapy uniformly demonstrate improved overall remission duration, even for high risk patients. [10] [11] The initial response to remission induction therapy is one of the most important prognostic factors in acute lymphoblastic leukaemia (ALL). Patients who respond slowly have a high risk of relapse, while those who fail to attain a complete remission within 4--6 weeks of treatment have dismal prognosis. 12 This study analyses the results of three to four-drug induction chemotherapy in the department of Paediatric Haemato-Oncology of Dhaka Shishu (Children) Hospital, Dhaka, Bangladesh.
Materials and Methods
This r etrospective study was conducted in the department of Paediatric Haemato-Oncology of Dhaka Shishu (Children) Hospital, Dhaka, Bangladesh from January 2013 to December 2015.
Total 221 newly diagnosed paediatric patients of ALL during this period were included in this study. Patients who had relapsed ALL, infantile leukaemia, and who were given chemotherapy elsewhere were excluded from the study. Patients remained admitted in the oncology ward for the whole duration of induction therapy.
After history and clinical examination, CBC, peripheral blood film and bone marrow biopsy/aspirate were seen for detection of blasts cells. Immunophenotyping by flowcytometry was done on peripheral blood sample or bone marrow aspirate for patients who were financially capable. Serum electrolytes, liver and renal function tests, tumour lysis profile, blood culture, CSF and chest radiography were a lso done. Patients were stabilised haemodynamically by packed cells transfusion if haemoglobin level was less than 8 gm/dL, platelets transfusion if platelet count was <20,000/mm 3 . Tumour lysis prophylaxis was started in the form of adequate hydration, allopurinol, phosphate binder and treatment of hyperkalemia and hypocalcaemia where n eeded. For febrile n eutropenia (ANC <1.0×109/L plus fever >38ºC (100.4ºF) for >4 hours or single spike of >38.5ºC (101.3ºF) proper antibiotics were started.
Parents of 40 patients out of 221 did not agree to start chemotherapy. In the rest 181 patients four-drug induction therapy was started according to Modified UKALL 2003 Protocol (Regimen A&B) with vincristine, dexamethasone/ prednisolone, L-asparaginase, a n d daunomycin. Intrathecal methotrexate, cytarabine and hydrocortisone were given on day 1 and day 28. Among them 14 patients discontinued chemotherapy and 10 patients died during chemotherapy. The rest 157 patients completed induction phase. Bone marrow study was repeated at the end of induction therapy to see the remission. Remission pattern was noted --whether complete remission (<5% blasts cells in the bone marrow), partial remission (5--25% blast cells) or no remission (>25% blast cells).
Results
Among the 221 patients, 146 (66%) were males and 75 (34%) were females. Mean age of the subjects was 5.5 years (2--14 years).
Pallor was noted in 201 (91%), fever in 186 (84%), bleeding manifestation in 99 (45%), hepatosplenomegaly in 177 (80%), lymphadenopathy in 139 (63%) a n d mediastinal mass in 7 (3.1%) patients (Fig 1) . Fig 1. Clinical manifestations of study subjects (n=221) 26 Total leucocyte count (TLC) was <50,000/mm 3 in 152 (69%) and >50,000/mm 3 in 69 (31%) patients. Blast cells were detected in 201 (91%) patients in peripheral blood film (PBF) with range of 2--96% and not detected in 20 (9%) patients. All the 221(100%) patients showed blast cells in bone marrow biopsy/aspirate. CSF from all the patients showed no blast cell (Fig 2) .
Fig 2. Laboratory profile of study subjects (n=221)
Parents of 40 (18%) patients r efused to start chemotherapy and parents of 14 (6%) patients could not continue chemotherapy due to financial constraint. Ten (5.5%) patients died due to bleeding, febrile neutropenia and sepsis during the course of induction therapy. The duration of induction phase was prolonged in many patients due to occurrence of agranulocytosis, thrombocytopenia, altered liver functions and due to lack of proper isolation as well as barrier nursing facilities.
Bone marrow study was done in remaining 157 patients after induction therapy. Out of 157 induction completed patients, 137 (87%) went into complete remission (<5% blast cells in bone marrow), 1 4 (9%) into partial remission (5--25% blast cells in bone marrow) and 6 (4%) was not in remission (>25% blast cells in the bone marrow) (Fig 3) . 
Discussion
It is widely accepted that the combination of dexamethasone/prednisolone, vincristine a n d Lasparaginase is essential for remission induction. The addition of daunomycin appears to be advantageous in high risk patients. 7, 8 A study by Laningham et al 13 showed that only 3% of patients had detectable CNS involvement at the time of diagnosis (>5 WBC/µL with lymphoblasts present). In our study, no patient presented with CNS leukaemia at diagnosis, so we administered only prophylactic intrathecal chemotherapy to all patients.
In comparison to developed countries, the incidence of drop-out of patients was more in our study. This might be due to poverty and misconception regarding outcome amongst our population.
Supportive care of the paediatric cancer patient has played a n increasingly important r ole in the management of these critically ill patients. As intensity of primary treatment has escalated, the side effects such as myelosuppression and infection have a lso increased. 14 MRC UK ALL X study showed that 2-3% of all patients died during induction or in remission, most frequently due to leucostasis, bleeding or opportunistic infections such a s Gram-negative septicaemia and pneumocystis carinii pneumonia. 15 In our study higher incidence of deaths (5.5%) during induction was observed as compared to 2-3% in the above study. It is mostly due to infection as there was lack of facilities for proper isolation and barrier nursing in our country.
According to a study by Silverman et al 16 , failure of induction therapy is a relatively rare event occurring in fewer than 5% of children with ALL treated with current r egimens, but in our study the failure of induction therapy was 4% which is similar.
Regarding prognosis after induction therapy, a study by Steinherzet al 17 explained that there are occasional patients who demonstrate partial remission (>5% but <25% leukaemic blasts) a t the end of a standard induction, but in our study the rate of partial remission was a little higher.
Some studies found different predictors for long term outcome of ALL children. 12, 13, 15 These predictors include age, WBC count, CNS involvement, gender, leukaemia morphology immunophenotyping, cytogenetics and rapidity to response. 18
Compete Remission
A study by Urban et a l 19 showed that improved supportive care has decreased the mortality rate during induction therapy to approximately 3% or less. But in spite of adequate supportive care and use of appropriate antibiotics, there is higher incidence of mortality (5.5%) in our patients. This may be due to (a) delayed referral to tertiary care centre, (b) complications of disease at the time of presentation, (c) poor nutrition status, (d) 4-drug induction therapy including daunomycin and (e) higher incidence of nosocomial/community acquired infections due to lack of facilities for isolation and barrier nursing.
In this study we have found that escalated four drug induction therapy causes more myelosuppression and infection during induction therapy, which warrants very strict barrier nursing and isolation. In our study high drop-out during induction therapy has been observed. Availability of drugs at lower cost and supportive social care may improve the condition.
Our study reveals that ALL in children is curable with effective chemotherapy. Poverty, ignorance a n d misconception regarding outcome are responsible for refusal and discontinuation of chemotherapy in third world countries like Bangladesh. Mortality and morbidity as well as treatment cost can be reduced with the improvement of the facilities for isolation, barrier nursing a n d supportive treatment a n d by creating awareness.
